Loggia Nicoletta 4

What Happened
Nicoletta Loggia, a director of Candel Therapeutics (CADL), was granted 381 shares as an award on 2026-06-30. The reported acquisition price is $8.64 per share, for a total reported value of $3,291. This was an award/grant (code A) of derivative securities that are stated to be fully vested at the time of grant — not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-30; Form 4 filed 2026-07-01 (timely; Form 4 due within two business days).
• Securities: 381 shares acquired as an award; reported price per share $8.64; total $3,291.
• Transaction type: A (award/grant); classified as a derivative acquisition with underlying shares fully vested at grant (per footnote).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: Award granted in lieu of normal quarterly cash payments; underlying award quantity fully vested at time of grant.
• No 10b5-1 plan, tax-withholding sale, or late filing flag reported in the provided data.

Context
This was a compensation-related award (converted from cash compensation) rather than a market purchase or sale. Such grants are common for directors and reflect compensation policy, not necessarily a direct buy/sell signal about the insider’s market outlook. Because the award was fully vested at grant, Loggia has immediate ownership of the underlying shares per the filing.